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 Circulating levels of small molecules or metabolites are highly heritable, but the impact of 56 
genetic differences in metabolism on human health is not well understood. In this cross-platform, 57 
genome-wide meta-analysis of 174 metabolite levels across six cohorts including up to 86,507 58 
participants (70% unpublished data), we identify 499 (362 novel) genome-wide significant 59 
associations (p<4.9×10-10) at 144 (94 novel) genomic regions. We show that inheritance of blood 60 
metabolite levels in the general population is characterized by pleiotropy, allelic heterogeneity, rare 61 
and common variants with large effects, non-linear associations, and enrichment for 62 
nonsynonymous variation in transporter and enzyme encoding genes. The majority of identified 63 
genes are known to be involved in biochemical processes regulating metabolite levels and to cause 64 
monogenic inborn errors of metabolism linked to specific metabolites, such as ASNS (rs17345286, 65 
MAF=0.27) and asparagine levels. We illustrate the influence of metabolite-associated variants on 66 
human health including a shared signal at GLP2R (p.Asp470Asn) associated with higher citrulline 67 
levels, body mass index, fasting glucose-dependent insulinotropic peptide and type 2 diabetes risk, 68 
and demonstrate beta-arrestin signalling as the underlying mechanism in cellular models. We link 69 
genetically-higher serine levels to a 95% reduction in the likelihood of developing macular 70 
telangiectasia type 2 [odds ratio (95% confidence interval) per standard deviation higher levels 0.05 71 
(0.03-0.08; p=9.5×10-30)]. We further demonstrate the predictive value of genetic variants identified 72 
for serine or glycine levels for this rare and difficult to diagnose degenerative retinal disease [area 73 
under the receiver operating characteristic curve: 0.73 (95% confidence interval: 0.70-0.75)], for 74 
which low serine availability, through generation of deoxysphingolipids, has recently been shown to 75 
be causally relevant. These results show that integration of human genomic variation with 76 
circulating small molecule data obtained across different measurement platforms enables efficient 77 
discovery of genetic regulators of human metabolism and translation into clinical insights. 78 




 Metabolites are small molecules that reflect biological processes and are widely measured in 81 
clinical medicine as diagnostic, prognostic or treatment response biomarkers1. Blood levels of 82 
metabolites are highly heritable with twin studies reporting a median explained variance in plasma 83 
levels of 6.9% and maximum of 50% depending on the metabolite2,3. Several earlier studies have 84 
started to characterise the genetic architecture of metabolite variation in the general population2–10, 85 
but been limited in size and scope by focussing on metabolites assessed using a single method. 86 
Integration of genetic association results for metabolites measured on different platforms can help 87 
maximise the power for a given metabolite and provide a more refined understanding of genetic 88 
influences on blood metabolite levels and human physiology.  89 
 To identify genomic regions regulating metabolite levels and systematically study their 90 
relevance for disease, we designed and conducted a cross-platform meta-analysis of genetic effects 91 
on levels of 174 blood metabolites measured in large-scale population-based studies. We included 92 
metabolites covered by the targeted Biocrates AbsoluteIDQ™ p180 platform and measured in the 93 
Fenland Study. We integrated unpublished data for any of these metabolites that were covered by 94 
the Nightingale (1H-NMR, Interval Study) or Metabolon (Discovery HD4™, EPIC-Norfolk and Interval 95 
Studies) platforms, or had previously been reported2,4,5. The focus on this targeted set of ‘platform-96 
specific’ metabolites enabled us to clearly map metabolites across platforms and maximise the 97 
sample size for each of the 174 metabolites for this proof of concept cross-platform GWAS study. To 98 
facilitate rapid sharing of our results, we developed a webserver 99 
(https://omicscience.org/apps/crossplatform/) that allows flexible interrogation of our results. 100 
Results 101 
Associations with blood metabolites at 144 genomic regions 102 
 Genome-wide meta-analyses were conducted for 174 metabolites from 7 biochemical classes 103 
(i.e. amino acids, biogenic amines, acylcarnitines, lyso-phosphatidylcholines, phosphatidylcholines, 104 
sphingomyelins and hexose) commonly measured using the Biocrates p180 kit in up to 86,507 105 
individuals, contributing over 3.7 million individual-metabolite data points (70% from unpublished 106 
studies; Fig. 1). For each of the 174 metabolites, this was the largest genome-wide association 107 
analyses (GWAS) to date, with at least a doubling of sample size (Fig. 1A). Sample sizes ranged from 108 
8,569 to 86,507 individuals for metabolites depending on the platform used in each contributing 109 
study. Using GWAS analyses we estimated the association of up to 10.2 million single nucleotide 110 
variants with a minor allele frequency (MAF) >0.5%, including 6.1 million with MAF ≥ 5%.  111 
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 We identified 499 variant-metabolite associations (362 novel) from 144 loci (94 novel) at a 112 
metabolome-adjusted genome-wide significance threshold of p<4.9×10-10 (correcting the usual 113 
GWAS-threshold, p<5x10-8, for 102 principal components explaining 95% of the variance in 114 
metabolite levels using principal component analysis; Fig. 1). The vast majority of these associations 115 
were consistent across studies and measurement platforms [median I2: 26.8 (interquartile range: 0 – 116 
70.1) for 465 associations with at least two contributing studies] (Supplementary Tab. S1-2). To 117 
identify possible sources of heterogeneity, we investigated the influence of differences by cohort, 118 
measurement platform, metabolite class, and association strength in a joint meta-regression model 119 
(Supplementary Tab. S3). This showed that heterogeneity was mainly due to the overall strength of 120 
the signal, i.e. associations with higher z-scores showed greater heterogeneity (p<1.05x10-9). 121 
However, the majority of these statistically heterogeneous associations were directionally consistent 122 
and nominally significant across and within each stratum for 146 of 170 associations with a z-score > 123 
10, demonstrating the feasibility of pooling association estimates across metabolomics platforms for 124 
the purpose of genetic discovery. Genetic variants at the NLRP12 locus, e.g. rs4632248, were a 125 
notable exception with large estimates of heterogeneity (I2>90%). The NLRP12 locus is known to 126 
affect the monocyte count11 and has been shown to have pleiotropic effects on the plasma 127 
proteome in the INTERVAL study12. Monocytes, or at least a subpopulation subsumed under this cell 128 
count measure, release a wide variety of biomolecules upon activation or may die during the sample 129 
handling process and hence releasing intracellular biomolecules, such as taurine13, into the plasma. 130 
In brief, one specific source of heterogeneity in mGWAS associations might relate to sample 131 
handling differences across studies.   132 
This highlights the utility of our genetic cross-platform approach to maximise power for a given 133 
metabolite, substantially extending previous efforts for any given metabolite14. Previously reported 134 
associations from platform-specific studies were also found to generally be consistent in our cross-135 
platform meta-analysis (Supplementary Tab. S2; https://omicscience.org/apps/crossplatform/). 136 
Insights in the genetic architecture of metabolite levels 137 
 We identified a median of 2 (range: 1-67, Fig. 2A) associated metabolites for each locus and a 138 
median of 3 (range: 1-20, Fig. 2B) locus associations for each metabolite, reflecting pleiotropy and 139 
the extensive contribution of genetic loci to circulating metabolite levels. The number of associations 140 
was proportional to the estimated heritability and the sample size of the meta-analysis for a given 141 
trait (Fig. 2C).  142 
 We applied a multi-trait statistical colocalisation method15 and identified between 1-30 143 
(median: 2) metabolites that did not meet the discovery p-value threshold, but showed high 144 
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posterior probability (>75%) of a shared genetic signal for 49 out of the 144 loci (Supplemental Fig. 145 
S1). Two distinct variants (rs2414577 and rs261334) nearby LIPC showed the largest gain in 146 
additionally associated metabolites, in line with previous reports of extensive pleiotropy and allelic 147 
heterogeneity at this locus9. We note that a low posterior probability for the alignment of multiple 148 
metabolites at other loci might be explained by the presence of multiple causal variants shared 149 
across multiple metabolites.  150 
 To systematically classify pleiotropic variants taking into account the correlation structure 151 
among metabolites we derived a data-driven metabolic network and performed community 152 
detection (see Methods and Supplemental Fig. S2). A total of 129 (60.5%) of 214 variants 153 
(associated with at least two metabolites at p<5x10-8) were associated with metabolites from at 154 
least two of the 14 communities (range: 2 – 11; Supplemental Fig. S2),  i.e. showed evidence for 155 
‘horizontal’ or broad pleiotropy. The most extreme variants included those near FADS1 (e.g. 156 
rs17455) associated with 61 metabolites across 11 communities at p<5x10-8. In contrast, rs2638315 157 
(likely tagging a missense variant rs2657879 at GLS2) was associated with nine metabolites within a 158 
single community and would therefore be considered as ‘horizontal pleiotropic’ for a well-defined 159 
group of correlated metabolites (Supplemental Fig. S2). 160 
 Similar to what is routinely observed in GWAS literature, effect size estimates increased with 161 
decreasing minor allele frequency (MAF) (Fig. 3A). However, there were 26 associations (Tab. 1) for 162 
common lead variants with per-allele differences in metabolites levels greater than 0.25 standard 163 
deviations (SD), a per-allele effect size that is >3-fold larger than the strongest common variants 164 
associated with SDs of body mass index at the FTO locus. 165 
 Variants identified in this study explained up to 23% of the variance (median: 1.4%; interquartile 166 
range: 0.5% - 2.8%) and up to 99.8% of the chip-based heritability (median 9.2%; interquartile range: 167 
4.7% - 17.1%) for the 141 metabolites with at least one genetic association (Fig. 2D). The 26 common 168 
variants with large effect sizes (>0.25 SD per allele) were identified for metabolites with higher 169 
heritability (Fig. 2D) and accounted for up to 74% of the heritability explained in those metabolites. 170 
 GWAS analyses generally assume a linear relationship between genotypes and phenotypes, i.e. 171 
an additive dose-response model. The identification of several metabolite-associated variants with 172 
large effect sizes and availability of individual-level data in the Fenland cohort allowed us to test 173 
whether the metabolite-associated variants showed evidence of deviation from a linear model. Of 174 
499 associations tested, 9 showed evidence of departure from a linear association (Fig. 2E-M). 175 
Modelling actual genotypes rather than assuming ‘additive’ linear associations in these instances 176 
explained a median of 7.4% more (range: 1.4-15.2%) of the heritability in metabolite levels (Fig. 2N). 177 
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Associations better described by an autosomal recessive or dominant model of inheritance might be 178 
the most likely explanation for this. Variant rs3916, for example, which showed a more than additive 179 
positive effect on butyrylcarnitine, is in perfect LD with a missense variant within ACADS  180 
(rs1799958, MAF=26%), which encodes for short-chain acyl-CoA dehydrogenase (SCAD). SCAD 181 
deficiency is an autosomal recessive disease diagnosed by elevated butyrylcarnitine concentrations 182 
in blood and homozygeous carrier status for established pathogenic variants16. 183 
 In 61 of the 499 associations the lead association signal was a nonsynonymous variant, a 40-fold 184 
enrichment compared to what would be expected by chance given the annotation of ascertained 185 
genetic variants (two-tailed binomial test, p=5×10-30, Fig. 3D). For a further 59 associations, the lead 186 
variant was in high LD with a nonsynonymous variant (r2>0.8). Lead variants that were 187 
nonsynonymous, or variants in high LD with a nonsynonymous variant, generally had lower MAF, 188 
larger effect sizes, and smaller 99%-credible sets (Supplemental Tab. S4) than variants that were not 189 
in these categories (Fig 3B-D).  190 
 We identified 22 loci harbouring two (n=21) or three (n=1) independent signals, i.e. different 191 
plasma metabolites were associated with distinct genetic variants within the same genomic region 192 
(Supplementary Tab. S2). For six regions, our two different annotations approaches assigned only 193 
one causal gene (see below and Methods), including ACADM, GLDC, ARG1, MARCH8, SLC7A2, and 194 
LIPC (Supplementary Tab. S2). We found evidence that allelic heterogeneity, i.e. conditionally 195 
independent variants at a locus for a specific metabolite, explains the association pattern at 3 of 196 
those loci (ACADM, ARG1, and LIPC; Supplementary Tab. S5). We identified another 16 loci 197 
harbouring at least one (range: 2–6) additional conditionally independent variant(s) in exact 198 
conditional analyses (see Methods, Supplementary Tab. S5).  199 
Effector genes, tissues, pathways  200 
 We used two complementary strategies to prioritize likely causal genes for the observed 201 
associations: (1) a hypothesis-free genetic approach based on physical distance, genomic annotation 202 
and integration of expression quantitative trait loci (eQTLs) to prioritize genes in a systematic and 203 
standardised way (see Methods), and (2) a biological knowledge-based approach integrating existing 204 
knowledge about specific metabolites or related pathways to identify biologically plausible 205 
candidate genes from the 20 genes closest to the lead variant (Fig. 4A). Using the hypothesis-free 206 
genetic approach, we identified 249 unique likely causal genes for the 499 associations, with at least 207 
one gene per association and some genes prioritized as likely causal for multiple metabolite 208 
associations. The knowledge-based approach identified 130 biologically plausible genes for 349 out 209 
of 499 associations. We asked whether the hypothesis-free genetic approach identified biologically 210 
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plausible genes (prioritized by strategy 2) more often than expected by chance. Amongst 9,980 211 
possible gene-metabolite pairs (20 genes x 499 associations), 420 (4.2%) were biologically plausible, 212 
condensed to 350 gene(s)-metabolite assignments after accounting for overlapping annotations. Of 213 
the latter, 126 pairs (36%) were identical to genetically-prioritized gene-metabolite pairs, 214 
representing a significant enrichment of biologically plausible genes among those prioritised by the 215 
hypothesis-free algorithm (~8-fold more than expected by chance; two-tailed binomial test, 216 
p=2.3×10-80; Fig. 4B). Among the consistently assigned genes between both approaches, assignment 217 
of the nearest gene (124 times out of 126, Χ2-test, p<2.5x10-45) was the strongest shared factor, as 218 
might be expected, followed by being  (or in LD with) a missense variant (R2>0.8, 30 times out of 126, 219 
Χ2-test, p<1.3x10-07) and only a minor contribution of eQTL data (20 times out of 126, Χ2-test, 220 
p<0.001). Over 70% of genetically prioritized genes were enzymes or transporters (Fig. 4C). 221 
Inconsistencies between the approaches might be explained by non-consideration of information on 222 
biological pathways in the hypothesis-free genetic approach, as well as variants acting more distal to 223 
the biological determinants of plasma metabolite levels not being considered in the knowledge-224 
based approach. The missense variant rs1260326 within GCKR, for example, colocalised with 49 225 
metabolites across diverse biochemical classes (Supplemental Fig. S1) and likely confers it effects on 226 
glucose metabolism through impaired inhibition of glucokinase by glucokinase regulatory protein 227 
and might hence be considered as putative causal candidate by the knowledge-driven approach for 228 
plasma glucose only. However, impairments in glucose metabolism result in numerous downstream 229 
consequences including more distal metabolic branches such as amino acid and lipid metabolism.  230 
 In addition to being enriched in genes previously implicated in the biology of these metabolites, 231 
the genetically prioritized genes were also enriched in genes known for mutations to cause rare 232 
inborn errors of metabolism (IEMs), i.e. monogenic defects in the metabolism of small molecules 233 
with very specific metabolite changes (Fig. 4B). 234 
 Integrating GWAS statistics across cohorts and platforms allowed us to identify three genes that 235 
have never been associated with any metabolite level so far. At the CERS6 locus, rs4143279 236 
associates with levels of sphingomyelin (d18:1/16:0) (p = 4.2x10-10). CERS6 encodes a ceramide 237 
synthase facilitating formation of ceramide, a precursor of sphingomyelins17. At the ASNS locus, 238 
rs17345286 associates with levels of asparagine (p = 4.7x10-20). The lead variant is in high LD (R2=1) 239 
with a missense mutation in ASNS (rs1049674, p.Val210Glu). ASNS encodes an asparagine 240 
synthase18. Finally, at the SLC43A1 locus, rs2649667 associates with levels of phenylalanine (p = 241 
3.6x10-13). SLC43A1 encodes a liver-enriched transporter of large neutral amino acids, including 242 
phenylalanine19. 243 
Insights into the causes of common and rare diseases from metabolite-associated loci 244 
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 The phenotypic consequences of metabolite-associated variants are currently not well 245 
characterized. Below, we investigate the contribution of individual loci and polygenic predisposition 246 
associated with differences in metabolite levels to the risk of common and rare diseases. 247 
A citrulline-raising functional variant in GLP2R increases type 2 diabetes risk 248 
 Because several of the metabolites captured in this GWAS have been associated with incident 249 
type 2 diabetes (T2D), we sought to investigate whether the association between metabolite-250 
associated loci and diabetes could provide insights into underlying pathophysiologic mechanisms. 251 
Using estimates of effect for association with T2D based on a meta-analysis of 80,983 cases and 252 
842,909 controls (see Methods), we observed a significant enrichment for associations with type 2 253 
diabetes (p-value=2.8x10-7) of metabolite-associated variants compared to a matched control set of 254 
variants (Fig. 5A).  255 
 Amongst the diabetes- and metabolite-associated loci was a missense p.Asp470Asn 256 
(rs17681684) variant in the GLP2R gene encoding the receptor for glucagon-like peptide 2, a 33 257 
amino acid peptide hormone encoded by the proglucagon gene (GCG) that stimulates the growth of 258 
intestinal tissue. Common variants at GLP2R are associated with an increased risk of T2D20. The 259 
previously reported lead variant for T2D (rs78761021) is in high LD (r²>0.87) with our lead citrulline 260 
association signal at GLP2R (rs17681684), which was associated with a 4% higher type 2 diabetes risk 261 
(per-allele odds ratio, 1.04; 95% confidence interval, 1.02, 1.05; p=1.1×10-08), comparable to 262 
previous reports20. Considering eleven phenotypes related to glucose homeostasis and metabolic 263 
health21–23, the A-allele of rs17681684 was significantly associated with insulin disposition index 264 
(beta=-0.067, p<0.002)22, corrected insulin response (beta=-0.061, p<0.004)22, glycated haemoglobin 265 
1c (HbA1c) (beta=0.006, p<0.0003)21, and body mass index (beta=0.010, p<5.3x10-9), in addition to 266 
the previously reported positive association with fasting glucose-dependent insulinotropic peptide 267 
(GIP) and the suggestive inverse association with post-glucose load GLP-1 (beta=-0.035, p<4.6x10-268 
4)24. While sample sizes and hence significance levels for insulin traits were not sufficient to support 269 
formal colocalisation analysis, we still obtained a high posterior probability (PP>75%) for a shared 270 
genetic signal across plasma citrulline, T2D risk, body mass index, and fasting levels of GIP (Fig. 5B). 271 
We noted, that the GLP2R p.Asp470Asn variant was the only of 6 independent genome-wide 272 
significant citrulline-raising loci that was associated with a higher risk of T2D, which indicates that 273 
the association does not reflect a general effect of blood citrulline levels on T2D risk but rather a 274 
locus-specific association at GLP2R (Fig. 5C). Plasma citrulline levels have been shown to reflect the 275 
volume of intestinal cells and are a marker of GLP2R target engagement in the treatment of short-276 
bowel syndrome with glucagon-like peptide 2 analogues25. Taken together, this suggests that 277 
genetically higher GLP2R signalling, indicated by the higher citrulline levels among GLP2R 470Asn 278 
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carriers, may lead to chronically elevated GIP (though increased enteroendocrine mass and number 279 
of GIP-secreting K-cells), which has been shown to downregulate GIP receptors on pancreatic beta 280 
cells26, thereby contributing to the observed reduction in the insulin secretory response and increase 281 
in T2D risk. 282 
 G-protein coupled receptors like GLP2R may signal via G-protein-dependent cyclic adenosine 283 
monophosphate (cAMP) production or via G-protein-independent beta-arrestin mediated 284 
signalling27. To investigate if the GLP2R p.Asp470Asn variant affects signalling via either of these 285 
pathways, we expressed the GLP2R p.Asp470Asn variant in different in vitro models (see Methods). 286 
We show that the variant allele is significantly associated with reduced recruitment of beta-arrestin 287 
to GLP2R upon glucagon-like peptide 2 stimulation, but not with cAMP signalling, which suggests a 288 
potential role for impaired beta-arrestin recruitment to GLP2R in the pathophysiology of type 2 289 
diabetes (Fig. 5E-G).  290 
Serine and glycine levels play a critical role in the aetiology of a rare eye disease 291 
 A recent GWAS of macular telangiectasia type 2 (MacTel), a rare neurovascular degenerative 292 
retinal disease, identified three genome-wide susceptibility loci (PHGDH, CPS1, and TMEM161B–293 
LINC00461) of which the same variants at PHGDH and CPS1 were associated with levels of the amino 294 
acids serine and glycine in this GWAS28. More recently, it was shown that low serine availability is 295 
linked to both MacTel as well as hereditary sensory and autonomic neuropathy type 1 through 296 
elevated levels of atypical deoxyshingolipids29. Whether genetic predisposition to low serine and 297 
glycine levels affects MacTel more generally or has predictive utility has not been investigated. To 298 
test this and to explore the specificity of associations between genetic influences on metabolite 299 
levels and the risk of MacTel, we generated genetic scores (GS) using the sentinel variants for each 300 
of the 141 metabolites with at least one significantly associated locus identified in this GWAS and 301 
tested their associations with the risk of MacTel. GS’s for serine and glycine were the only scores 302 
associated with risk for MacTel after removal of the known highly pleiotropic GCKR variant (Fig. 6A). 303 
Each standard deviation higher serine levels via the serine GS was associated with a 95% lower risk 304 
of MacTel (odds ratio (95% confidence interval), 0.05 (0.03-0.08); p=9.5×10-30; Fig. 6A). Each of five 305 
serine associated variants was individually associated with lower MacTel risk, with a clear dose-306 
response relationship and no evidence of heterogeneity (Fig. 6B). The association was unchanged 307 
when removing the GCKR locus. To disentangle the effect of these two highly correlated metabolites 308 
on MacTel risk, we used multivariable Mendelian randomization analysis, which allowed us to test 309 
for a causal effect of both measures simultaneously. In this analysis, the effect of serine remained 310 
strong, while the effect of glycine was attenuated (Tab. 2). Glycine and serine can be interconverted 311 
and these results provide genetic evidence that the link between glycine and MacTel is via serine 312 
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levels through glycine conversion. This hypothesis is supported by the evidence of a log-linear 313 
relationship between associations with serine and risk of MacTel among glycine-associated variants 314 
(Fig. 6B). These findings provide strong evidence that pathways indexed by genetically higher serine 315 
levels are strongly and causally associated with protection against MacTel. 316 
 Given the large observed effect size, we estimated whether using serine and glycine-associated 317 
loci might improve the prediction of this rare disease. Adding genetically predicted glycine and 318 
serine levels, based on newly discovered metabolite instruments from the present study and 319 
previous MacTel variants linked to glycine and serine metabolism, substantially improved prediction 320 
of MacTel based on an area under the receiver operating characteristic curve from 0.65 (CI 95%: 321 
0.626-0.682) to 0.73 (0.702-0.753) (Fig. 6).  322 
Common variation at inborn error of metabolism (IEM) associated genes influences the risk of 323 
common manifestations of diseases related to the phenotypic presentation of those IEMs 324 
 In his seminal 1902 work on alkaptonuria30, also known as dark or black urine disease, Archibald 325 
Garrod was the first to hypothesise that inborn errors of metabolism are “extreme examples of 326 
variations of chemical behaviour which are probably everywhere present in minor degrees”. 327 
Previous studies have shown enrichment of metabolite quantitative trait loci in genes known to 328 
cause IEMs31. Whether or not common variants at IEM causing loci translate into clinically manifest 329 
disease remains unknown. The identification of several metabolite-associated variants at IEM-linked 330 
genes in this GWAS meta-analysis allows an investigation of the health consequences of genetically 331 
determined differences in metabolism for more frequently occurring variants, representing 332 
potentially milder forms of the metabolic and other clinical symptoms of IEMs, and providing new 333 
candidate genes for rare extreme metabolic disorders that currently lack a genetic basis (Fig. 7A). In 334 
this study, there were 153 locus-metabolite associations for which 53 unique IEM-associated genes 335 
were prioritized as likely causal using either the hypothesis-free genetic approach or the knowledge-336 
based approach on the basis of the Orphanet database32. In 89% of these associations (136 of 153) 337 
the metabolite associated with a given GWAS locus perfectly matched, or was closely related to, the 338 
metabolite affected in patients with the corresponding IEM (Fig. 7B).  339 
 To test whether IEM-mirroring lead variants from our metabolite GWAS may increase the risk of 340 
common manifestations of diseases known to exist in patients with the corresponding IEM (Fig. 7A) 341 
we obtained a list of electronic health record diagnosis codes (International Statistical Classification 342 
of Diseases and Related Health Problems 10th Revision [ICD-10]) and mapped those based on 343 
symptoms seen in both, IEM patients and patients with common, complex disease manifestations 344 
(see Methods). We identified 93 ICD-10 codes with at least 500 cases within the UK Biobank study 345 
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that aligned with the symptoms or presentations seen in patients with IEMs caused by mutations in 346 
genes specifically associated with metabolites observed in the present study. We obtained the 347 
association statistics of 85 unique metabolite-associated lead variants at the 136 locus-metabolite 348 
associations with these 93 clinical diagnoses and observed 36 associations that met statistical 349 
significance (false discovery rate < 5%, Supplemental Table S6 and Fig. 7B). For 15 out of those we 350 
obtained strong evidence of a shared genetic metabolite-phenotype signal using colocalisation 351 
analyses (posterior probability of a shared signal >80%; Fig. 7D and Supplemental Fig. S3). These 352 
instances linked common genetic variants in or near APOE, PCSK9, LPL, and LDLR associated with 353 
sphingomyelins (SM 16:0, SM 18:0, and SM-OH 24:1) with atherosclerotic heart disease diagnosis 354 
codes (I21, I25), mirroring what is observed in rare familial forms of dyslipidaemia in which these 355 
sphingomyelins are elevated and the risk of ischemic heart disease is greatly increased33,34. These 356 
results provide further evidence that common variation at IEM genes can lead to clinical phenotypes 357 
and diseases that correspond to those that patients with rare mutations in those same genes are 358 
severely affected by. Further studies with detailed follow-up for specific outcomes may provide 359 
greater power and help clarify the medical consequences of genetic differences in metabolism 360 
caused by metabolite altering variants in the general population. 361 
Discussion 362 
 This large-scale genome-wide meta-analysis has integrated genetic associations for 174 363 
metabolites across different measurement platforms, an approach that has resulted in a three-fold 364 
increase in our knowledge of genetic loci regulating levels of these metabolites. We assign likely 365 
causal genes for many of the identified associations using a dual approach that combined automated 366 
database mining with manual curation. 367 
 Previous platform-specific genetic studies of blood metabolites have been substantially smaller 368 
in size due to being restricted to a single platform and/ or study2–10. We build on these earlier studies 369 
to identify and demonstrate enrichment of rare and low-frequency coding variants in enzyme and 370 
transporter genes with large effects and reveal the importance of non-linear associations at several 371 
loci.  372 
 Our results not only provide detailed insight into the genetic determinants of human 373 
metabolism but consider their relevance for disease aetiology and prediction. We explore both 374 
locus-specific and polygenic score effects and provide tangible examples with clear translational 375 
potential. We discovered a strong link between GLP2R, citrulline metabolism and T2D, and 376 
demonstrate that the p.Asp470Asn variant underlying the citrulline and T2D associations leads to 377 
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significantly reduced recruitment of beta-arrestin to GLP2R in various cellular models, providing an 378 
explanation for a possible pathological mechanism of a variant previously predicted to be benign24. 379 
 The finding that a standard deviation increase in serine levels via a genetic score is associated 380 
with 95% lower risk of MacTel shows that genetic differences resulting in very specific metabolic 381 
consequences can have profound effects on health. Our results suggest that inclusion of genetic 382 
scores for metabolite levels can improve identification of high risk individuals. Serine and glycine 383 
supplementation and/ or pharmacologic modulation of serine metabolism may help to reduce 384 
development or alter the prognosis of this rare, severe eye disease, specifically if targeted to people 385 
genetically with a genetic susceptibility to low serine levels. It is important to note, that randomized 386 
control trials are needed testing this hypothesis before any recommendations on supplementations 387 
could be made.   388 
 We finally show specific examples where common genetic variation in IEM-related genes is 389 
associated with phenotypes that are also caused by rare highly penetrant mutations. These results 390 
suggest that rare variants in metabolite regulating genes newly identified in our study may be 391 
valuable candidate genes in patients without a genetic diagnosis but severe alterations in the 392 
corresponding or related metabolites. Hence these results provide a new starting point for further 393 
investigations into the relationships between human metabolism and common and rare disorders.   394 




Study design and participating cohorts 397 
 We performed genome-wide meta-analyses of the levels of 174 metabolites from 7 biochemical 398 
categories (amino acids, biogenic amines, acylcarnitines, phosphatidylcholines, 399 
lysophosphatidylcholines, sphingomyelins, and sum of hexoses) captured by the Biocrates p180 kit 400 
measured using mass spectrometry (MS). As described in more detail below, a total of 174 401 
metabolites were successfully measured in up to 9,363 plasma samples from genotyped participants 402 
of the Fenland study35. 403 
 To maximise sample size and power, we meta-analysed genome-wide association (GWAS) 404 
results from the Fenland cohort with those run in the EPIC-Norfolk 36 and INTERVAL 37 studies, in 405 
which metabolites were profiled using MS (Metabolon Discovery HD4 platform) or protein nuclear 406 
magnetic resonance (1H-NMR) spectrometry 3839 (Supplementary Tab. 1). Ten of the 174 Biocrates 407 
metabolites were covered across all platforms, while 38 were available on the Biocrates and 408 
Metabolon platforms and 126 were unique to Biocrates (Fig. 1). We integrated publicly available 409 
summary statistics from genome-wide meta-analyses of the same metabolites measured using MS 410 
(with Biocrates or Metabolon platforms) or 1H-NMR spectrometry (Supplementary Tab. 1). 411 
Metabolites were matched across platforms by comparing metabolite names and biochemical 412 
formulas. Mapping across different Metabolon platforms was done based on retention time/index 413 
(RI), mass to charge ratio (m/z), and chromatographic data (including MS/MS spectral data). 414 
Scientists at Metabolon Inc. independently reviewed and confirmed metabolite matches. 415 
 A summary of the characteristics of participating cohorts is given in Supplemental Table S1. The 416 
Fenland study is a population-based cohort study of 12,435 participants without diabetes born 417 
between 1950 and 1975 35. Participants were recruited from general practice surgeries in Cambridge, 418 
Ely and Wisbech (United Kingdom) and underwent detailed metabolic phenotyping and genome-419 
wide genotyping. Ethical approval for the Fenland study was given by the Cambridge Local Ethics 420 
committee (ref. 04/Q0108/19) and all participants gave their written consent prior to entering the 421 
study. The European Prospective Investigation of Cancer (EPIC)-Norfolk study is a prospective cohort 422 
of 25,639 individuals aged between 40 and 79 and living in the county of Norfolk in the United 423 
Kingdom at recruitment 36. The study was approved by the Norfolk Research Ethics Committee (REC 424 
ref. 98CN01) and all participants gave their written consent before entering the study. INTERVAL is a 425 
randomised trial of approximately 50,000 whole blood donors enrolled from all 25 static centres of 426 
NHS Blood and Transplant, aiming to determine whether donation intervals can be safely and 427 
acceptably decreased to optimise blood supply whilst maintaining the health of donors37. All 428 
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participants of the study gave written informed consent and the study was approved by NRES 429 
Committee East of England - Cambridge East (ref. 11/EE/0538). 430 
Metabolomics measurements 431 
 The levels of 174 metabolites were measured in the Fenland study by the AbsoluteIDQ® 432 
Biocrates p180 Kit (Biocrates Life Sciences AG, Innsbruck, Austria) as reported elsewhere in 433 
detail39,40. We used a Waters Acquity ultra-performance liquid chromatography (UPLC; Waters ltd, 434 
Manchester, UK) system coupled to an ABSciex 5500 Qtrap mass spectrometer (Sciex ltd, 435 
Warrington, UK). Samples were derivatised and extracted using a Hamilton STAR liquid handling 436 
station (Hamilton Robotics Ltd, Birmingham, UK). Flow injection analysis coupled with tandem mass 437 
spectrometry (FIA-MS/MS) using multiple reaction monitoring (MRM) in positive mode ionisation 438 
was performed to measure the relative levels of acylcarnitines, phosphatidylcholines, 439 
lysophosphatidylcholines and sphingolipids. The level of hexose was measured in negative ionisation 440 
mode. Ultra-performance liquid chromatography coupled with tandem mass spectrometry using 441 
MRM was performed to measure the concentration of amino acids and biogenic amines. The 442 
chromatography consisted of a 5-minute gradient starting at 100% aqueous (0.2% Formic acid) 443 
increasing to 95% acetonitrile (0.2% Formic acid) over a Waters Acquity UPLC BEH C18 column (2.1 x 444 
50 mm, 1.7 μm, with guard column). Isotopically labelled internal standards are integrated within 445 
the Biocrates p180 Kit for quantification. Data was processed in the Biocrates MetIDQ software. Raw 446 
metabolite readings underwent extensive quality control procedures. Firstly, we excluded from any 447 
further analysis metabolites for which the number of measurements below the limit of 448 
quantification (LOQ) exceeded 5% of measured samples. Excluded metabolites were carnosine, 449 
dopamine, putrescine, asymmetric dimethyl arginine, dihydroxyphenylalanine, nitrotyrosine, 450 
spermine, sphingomyelines SM(22:3), SM(26:0), SM(26:1), SM(24:1-OH), phosphatidylcholine acyl-451 
alky 44:4, and phosphatidylcholine diacyl C30:2. Secondly, in samples with detectable but not 452 
quantifiable peaks, we assigned random values between 0 and the run-specific LOQ of a given 453 
metabolite. Finally, we corrected for batch-effects with a “location-scale” approach, i.e. with 454 
normalization for mean and standard deviation of batches. 455 
 The levels of up to 38 metabolites were measured in EPIC-Norfolk and INTERVAL using the 456 
Metabolon HD4 Discovery platform. Measurements were carried out using MS/MS instruments. For 457 
these measurements, instrument variability, determined by calculating the median relative standard 458 
deviation, was of 6%. Data Extraction and Compound Identification: raw data was extracted, peak-459 
identified and quality control-processed using Metabolon’s hardware and software. Compounds 460 
were identified by comparison to library entries of purified standards or recurrent unknown entities. 461 
Metabolon maintains a library, based upon authenticated standards, that contains the retention 462 
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time/index (RI), mass to charge ratio (m/z), and chromatographic data (including MS/MS spectral 463 
data) of all molecules present in the library. Identifications were based on three criteria: retention 464 
index, accurate mass match to the library +/- 10 ppm, and the MS/MS forward and reverse scores 465 
between the experimental data and authentic standards. Metabolite Quantification and Data 466 
Normalization: Peaks were quantified using area-under-the-curve. A data normalization step was 467 
performed to correct variation resulting from instrument inter-day tuning differences. Essentially, 468 
each compound was corrected in run-day blocks by registering the medians to equal one (1.00) and 469 
normalizing each data point proportionately (termed the “block correction”). 470 
 The serum levels of 230 metabolites were measured in the INTERVAL study using 1H-NMR 471 
spectroscopy38,41. Among those, 10 metabolites (creatinine, alanine, glutamine, glycine, histidine, 472 
isoleucine, leucine, valine, phenylalanine, and tyrosine) overlapped with what is captured by the 473 
Biocrates p180 Kit and were used in the present study. Further details of the 1H-NMR spectroscopy, 474 
quantification data analysis and identification of the metabolites have been described previously38,42. 475 
Participants with >30% of metabolite measures missing and duplicated individuals were removed. 476 
Metabolite data more than 10 SD from the mean was also removed. 477 
GWAS and meta-analysis 478 
 In Fenland and EPIC-Norfolk, metabolite levels were natural log-transformed, winsorised to 479 
five standard deviations and then standardised to a mean of 0 and a standard deviation of 1. 480 
Genotypes were measured using Affymetrix Axiom or Affymetrix SNP5.0 genotyping arrays. In brief, 481 
genotyping in Fenland was done in two waves including 1,500 (Affymetrix SNP5.0) and 9,369 482 
(Affymetrix Axiom) participants and imputation was done using IMPUTE2 to 1000 Genomes Phase 483 
1v3 (Affymetrix SNP5.0) or phase 3 (Affymetrix Axiom) reference panels (Supplemental Tab. S1). 484 
Plasma metabolite and genotype data was available for 8,714 (Affymetrix Axiom) and 1,022 485 
(Affymetrix SNP5.0) unrelated individuals. In EPIC-Norfolk, 21,044 samples were forwarded to 486 
imputation using 1000 Genomes Phase 3 (Oct. 2014) reference panels (Supplemental Tab. S1). 487 
Imputed SNPs with imputation quality score less than 0.3 or minor allele account less than 2 were 488 
removed from the imputed dataset. Genome-wide association analyses were carried out using BOLT-489 
LMM v2.2 adjusting for age, sex, and study-specific covariates in mixed linear models. Alternatively 490 
(when the BOLT-LMM algorithm failed due to heritability estimates close to zero or one) analyses 491 
were performed using SNPTEST v2.4.1 in linear regression models, additionally adjusting for the top 492 
4 genetic ancestry principal components and excluding related individuals (defined by proportion 493 
identity-by-descent calculated in Plink43 > 0.1875 as recommended44). GWAS analyses in Fenland 494 
were performed within genotyping chip, and associations meta-analysed.  495 
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 In INTERVAL, genotyping was conducted using the Affymetrix Axiom genotyping array. Standard 496 
quality control procedures were conducted prior to imputation. The data were phased and imputed 497 
to a joint 1000 Genomes Phase 3 (May 2013)-UK10K reference imputation panel. After QC, a total of 498 
40,905 participant remained with data obtained by 1H-NMR spectroscopy. For variants with a MAF 499 
of >1% and imputed variants with an info score of >0.4 a univariate GWAS for each of the ten 500 
metabolic measures was conducted, after adjustment for technical and seasonal effects, including 501 
age, sex, and the first 10 principal components, and rank-based inverse normal transformation. The 502 
association analyses were performed using BOLT-LMM v2.2 and R. Data based on the Metabolon 503 
HD4 platform was available for 8,455 participants. Prior to the Metabolon HD4 genetic analysis, 504 
genetic data were filtered to include only variants with a MAF of >0.01% and imputed variants with 505 
an info score of >0.3. Phenotype residuals corrected for age, gender, metabolon batch, INTERVAL 506 
centre, plate number, appointment month, the lag time between the blood donation appointment 507 
and sample processing, and the first 5 ancestry principal components were calculated for each 508 
metabolite and the residuals were standardised prior to the genetic analyses in SNPTEST v2.5.1.  509 
 For all GWAS analysis within Fenland, EPIC-Norfolk and INTERVAL, variants with Hardy-510 
Weinberg equilibrium p<1⨯10-6 and associations with absolute value of effect size >5 or standard 511 
error (SE) >10 or <0 were excluded; insertions and deletions were excluded.  512 
 For each metabolite, we performed a meta-analysis of z-scores (betas divided by standard 513 
errors) as a measure of association, signals and loci (see below), using METAL software. 514 
Heterogeneity between studies for each association was estimated by Cochran’s Q-test. For each 515 
metabolite, we also performed a meta-analysis of beta and standard errors for the subset of studies 516 
(Fenland and, when available, EPIC-Norfolk and/or INTERVAL) where we had access to individual 517 
level data and standardised phenotype preparation to estimate effect sizes. Quality filters 518 
implemented after meta-analysis included exclusion of SNPs not captured by at least 50% of the 519 
participating studies and 50% of the maximum sample size for that metabolite and variants with a 520 
minor allele frequency below 0.5%. As a result, meta-analyses assessed the associations of up to 521 
13.1 million common or low-frequency autosomal SNPs. Chromosome and base pair positions are 522 
determined referring to GRCh37 annotation. To define associations between genetic variants and 523 
metabolites, we corrected the conventional threshold of genome wide significance for 102 tests (i.e. 524 
p<4.9x10-10), corresponding to the number of principal components explaining 95% of the variance 525 
of the 174 metabolites in the Fenland cohort, as previously described45. 526 
Signal selection 527 
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 For each metabolite, we ranked associated SNPs (p <4.9x10-10) by z-score to select trait-sentinel 528 
SNPs and defined an “association” region as the region extending 1 Mb to each side of the trait-529 
sentinel SNP. During forward selection of trait-sentinel SNPs and loci for each trait, adjacent and 530 
partially overlapping association regions were merged by extending region boundaries to a further 1 531 
Mb. After defining trait-sentinel SNPs and association regions we defined overall lead-sentinel SNP 532 
and loci for any metabolite using a similar approach. Trait-sentinel SNPs were sorted by z-score for 533 
the forward selection of lead-sentinel SNPs and a “locus” was defined as the region extending 1 Mb 534 
each side of the lead-sentinel SNP. Regions larger than 2 Mb defined in the trait-sentinel association 535 
region definition were carried over in the definition of lead-sentinel SNP loci. As a result, all lead-536 
sentinel SNPs were >1Mb apart from each other and had very low or no linkage disequilibrium (R2 < 537 
0.05). 538 
 For a given locus, independent signals across metabolites were determined based on linkage 539 
disequilibrium (LD)-clumping of SNPs that reached the Bonferroni corrected p-value. SNPs with the 540 
smallest p-values and an R2 less than 0.05 were identified as independent signals. LD patterns were 541 
estimated with SNP genotype data imputed using the haplotype reference consortium (HRC) 542 
reference panel, with additional variants from the combined UK10K plus 1000 Genomes Phase 3 543 
reference panel in the EPIC-Norfolk study (n = 19,254 after removing ancestry outliers and related 544 
individuals).  545 
 Throughout the manuscript, the term “locus” indicates a genomic region (≥1 Mb each side) of a 546 
lead-sentinel SNP harbouring one or more trait-sentinel SNPs; “signal” indicates a group of trait-547 
sentinel SNPs in LD with each other but not with other trait-sentinel SNPs in the locus (R2 < 0.05); 548 
“association” indicates trait-sentinel SNP to metabolite associations defined by a trait-lead SNP and 549 
its surrounding region (≥1 Mb each side). 550 
 We tested at each locus for conditional independent variants using exact stepwise conditional 551 
analysis in the largest Fenland sample (n = 8,714) using SNPTEST v2.5 with the same baseline 552 
adjustment as in the discovery approach. To refine signals at those loci we used a more recent 553 
imputation for this analysis based on the HRC v1 reference panel and additional SNPs imputed using 554 
UK10K and 1000G phase 3. We defined secondary signals as those with a conditional p-value < 5x10-555 
8. To avoid problems with collinearity we tested after each round if inclusion of a new variant 556 
changed associations of all previous variants with the outcome using a joint model. If this model 557 
indicated that one or more of the previously selected variants dropped below the applied 558 
significance threshold we stopped the procedure, otherwise we repeated this procedure until no 559 
further variant met the significance threshold in conditional models. We considered only locus–560 
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metabolite associations meeting the GWAS-threshold for significance in the Fenland analysis 561 
(n=228).  562 
Investigation of heterogeneity 563 
 We used a meta-regression model to identify factors associated with larger I² values across all 564 
499 identified SNP-metabolite associations. To this end, a vector of heterogeneity estimates, I², from 565 
the meta-analysis was obtained as outcome and the following explanatory variables were 566 
considered: strength of effect (absolute Z-score of the SNP – metabolite association), biochemical 567 
class, dummy variables indicating the study of origin (related to the measurement platform), and the 568 
number of contributing studies as an estimate of sample size. A significant effect of any of those 569 
terms in a linear regression model was taken to indicate a source of heterogeneity across SNP-570 
metabolite associations and hence identified systematic factors contributing to any observed cross-571 
platform heterogeneity. 572 
Statistical fine-mapping 573 
 We used statistical fine mapping to determine 99%-credible intervals for all independently 574 
associated SNPs using the R package ‘corrcoverage’. Briefly, regional summary statistics (betas and 575 
standard errors) were converted to approximate Bayes factors as described in Wakefield et al.46 to 576 
calculate the posterior probability (PP) for each variant driving the association. Credible sets are 577 
subsequently defined as the ranked list of variants cumulatively covering 99% of the PP to cover the 578 
true causal signal. For loci with evidence of independent secondary signals we used GCTA COJO-cond 579 
algorithm to generate conditional association statistics conditioning on all other independent signals 580 
in the locus. Since the calculation of approximate Bayes factors requires betas and standard errors 581 
we used meta-analysis results across studies for which we had access to individual data (Fenland, 582 
EPIC-Norfolk, and INTERVAL). However, out of 546 detected signals 473 reached genome-wide 583 
significance (p<5x10-8) in this smaller subset and we restricted fine-mapping to those associations. 584 
Muli-trait colocalisation across metabolites 585 
 We used hypothesis prioritisation in multi-trait colocalisation (HyPrColoc)15 at each of the 586 
identified 144 loci 1) to identify metabolites sharing a common causal variant over and above what 587 
could be identified in the meta-analysis to increase statistical power, and 2) to identify loci with 588 
evidence of multiple causal variants with distinct associated metabolite clusters. Briefly, HyPrColoc 589 
aims to test the global hypothesis that multiple traits share a common genetic signal at a genomic 590 
location and further uses a clustering algorithm to partition possible clusters of traits with distinct 591 
causal variants within the same genomic region. HyPrColoc provides for each cluster three different 592 
types of output: 1) a posterior probability (PP) that all traits in the cluster share a common genetic 593 
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signal, 2) a regional association probability, i.e. that all the metabolites share an association with one 594 
or more variants in the region, and 3) the proportion of the PP explained by the candidate variant. 595 
We considered a highly likely alignment of a genetic signal across various traits if the PP > 75% or the 596 
regional association probability > 80% and the PP > 50%. The second criterion takes into account 597 
that metabolites may share multiple causal variants at the same locus. We used the same set of 598 
summary statistics as described for statistical fine-mapping, i.e. based on betas and standard errors 599 
across studies for which we had access to individual level data. We further filtered metabolites with 600 
no evidence of a likely genetic signal (p>10-5) in a region before performing HyPrColoc, which 601 
improved clustering across traits by minimizing noise. We used the same workflow to test for the 602 
alignment of a genetic signal at the GLPR2 locus using summary statistics from T2D (see below), a 603 
meta-analysis for body mass index across GIANT and UK Biobank, plasma GIP, and plasma citrulline. 604 
Testing for non-linear effects 605 
 We tested each of the 499 identified SNP (j) – metabolite (i) pairs for the deviation from an 606 
additive linear model by introducing a dummy variable encoding heterozygous carriers (D), i.e. D = 1 607 
if heterozygous and 0 otherwise, in the following regression model: 608 	~	 +	 ∗ +	 ∗ 	 + ⋯ …+ 	   609 
A significant estimate indicates departure from linearity. In a more formal framework this test 610 
allows to test for either a dominant negative or positive model of inheritance depending on the 611 
coding of the effect allele. We implemented this test in STATA version 13 using individual level data 612 
from the Fenland cohort. 613 
Metabolic network and community detection 614 
 We used Gaussian graphical modelling (GGMs) to construct a metabolic network across all 174 615 
metabolites in a data-driven manner2. Briefly, GGMs are based on partial correlation minimizing 616 
confounding and have been shown to recover tight biochemical dependencies from single spot 617 
blood measurements. The final network comprised 167 metabolites and 554 significant (p<3.3x10-6) 618 
edges. We next preformed community detection using the Girvan-Newman algorithm, which 619 
successively removes edges with high edge betweenness creating a dendrogram of splits of the 620 
network into communities, as implemented in the R package igraph. We obtained 14 distinct 621 
communities including those covering metabolites of distinct biochemical species as well as 622 
subdividing larger metabolite classes (Supplemental Fig. S2). 623 
Hypothesis-free (genetic) assignment of causal genes 624 
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 To assign likely causal genes to lead SNPs at each locus we generated a scoring system. We 625 
identified the nearest gene for each variant by querying HaploReg47. Next we integrated expression 626 
quantitative trait loci (eQTL) studies (GTEx v6p) to identify genes whose expression levels are 627 
associated with metabolite levels using TWAS/FUSION (Transcriptome-wide association study / 628 
Functional summary-based imputation)48. In doing so, we assigned to each variant-metabolite 629 
association one or more associated genes using the variant as common anchor. We further assigned 630 
higher impact for a causal gene if either the metabolite variant itself or a proxy in high linkage 631 
disequilibrium (R2>0.8) was a missense variant for a known gene again using the HaploReg database 632 
to obtain relevant information. Based on those three criteria we ranked all possible candidate genes 633 
and kept those with the highest score as putative causal gene. 634 
Knowledge-based (biological) assignment of causal genes 635 
 Metabolite traits are unique among genetically evaluated phenotypes in that the functional 636 
characterization of the relevant genes has often already been carried out using classic biochemical 637 
techniques. The objective for the knowledge-based assignment strategy was to find the 638 
experimental evidence that has previously linked one of the genes proximal to the GWAS lead 639 
variant to the relevant metabolite. For many loci and metabolites this ‘retrospective’ analysis has 640 
already been carried out 3149.For these cases, previous causal gene assignments were generally 641 
adopted. For novel loci, we employed a dual strategy that combined automated database mining 642 
with manual curation. In the automated phase, seven approaches were employed to identify 643 
potential causal genes among the 20 protein-coding genes closest to each lead variant, as described 644 
in detail below, using the shortest distance determined from the lead SNP to each gene’s 645 
transcription start site (TSS) or transcription end site (TES), with a distance value of 0 assigned if the 646 
SNP fell between the TSS and TES.   647 
These 7 approaches were as follows: 648 
1) HMDB metabolite names50 were compared to each entrez gene name;  649 
2) Metabolite names were compared to the name and synonyms of the protein encoded by each 650 
gene51 651 
3) HMDB metabolite names and their parent terms (class) were compared to the names for the 652 
protein encoded by each gene (UniProt). 653 
4) Metabolite names were compared to rare diseases linked to each gene in OMIM32 after 654 
removing the following non-specific substrings from disease names: uria, emia, deficiency, disease, 655 
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transient, neonatal, hyper, hypo, defect, syndrome, familial, autosomal, dominant, recessive, benign, 656 
infantile, hereditary, congenital, early-onset, idiopathic; 657 
5) HMDB metabolite names and their parent terms were compared to all GO biological processes 658 
associated with each gene after removing the following non-specific substrings from the name of the 659 
biological process: metabolic process, metabolism, catabolic process, response to, positive 660 
regulation of, negative regulation of, regulation of. For this analysis only gene sets containing fewer 661 
than 500 gene annotations were retained. 662 
6) KEGG maps52 containing the metabolite as defined in HMDB were compared to KEGG maps 663 
containing each gene, as defined in KEGG. For this analysis the large “metabolic process” map was 664 
omitted. 665 
7) Each proximal gene was compared to the list of known interacting genes as defined in HMDB. 666 
For each text-matching based approach, a fuzzy text similarity metric (pair coefficient) as encoded in 667 
the ruby gem “fuzzy_match” was used with a score greater than 0.5 considered as a match. 668 
In the next step, all automated hits at each locus were manually reviewed for plausibility. In 669 
addition, other genes at each locus were reviewed if the Entrez gene or UniProt description of the 670 
gene suggested it could potentially be related to the metabolite. If existing experimental evidence 671 
could be found linking one of the 20 closest genes to the metabolite, that gene was selected as the 672 
biologically most likely causal gene. If no clear experimental evidence existed for any of the 20 673 
closest protein coding genes, no causal gene was manually selected. In a few cases multiple genes at 674 
a locus had existing experimental evidence. This frequently occurs in the case of paralogs with 675 
similar molecule functions. In these cases, all such genes were flagged as likely causal genes. 676 
For each manually selected causal gene, the earliest experimental evidence linking the gene 677 
(preferably the human gene) to the metabolite was identified. The median publication year for the 678 
identified experimental evidence was 2000. 679 
Enrichment of type 2 diabetes associations among metabolite associated lead variants 680 
 We examined whether the set of independent lead metabolite associated variants (N=168) 681 
were enriched for associations with type 2 diabetes. We plotted observed versus expected -log10(p 682 
values) for the 168 lead variants in a QQ-plot, using association statistics from a type 2 diabetes 683 
meta-analysis including 80,983 cases and 842,909 non-cases from the DIAMANTE study 53 (55,005 684 
T2D cases, 400,308 non-cases), UK Biobank54 (24,758 T2D cases, 424575 non-cases, application 685 
number 44448) and the EPIC-Norfolk study (additional T2D cases not included in DIAMANTE study: 686 
1,220 T2D cases and 18,026 non-cases). This QQ-plot was compared to those for 1000 sets of 687 
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variants, where variants in each set were matched to the index metabolite variants in terms of MAF, 688 
the number of variants in LD (R2>0.5), gene density and distance to nearest gene (for all parameters 689 
+/- 50% of the index variant value), but otherwise randomly sampled from across the autosome 690 
excluding the HLA region. MAF and LD parameters for individual variants were determined from the 691 
EPIC-Norfolk study (using the combined HRC, UK10K and 1000G imputation as previously described) 692 
and gene information was derived from GENCODE v19 annotation55. A one-tailed Wilcoxon rank sum 693 
test was used to compare the distribution of association –log10 p-values for the metabolite 694 
associated variants with that for the randomly sampled, matched, variants. 695 
Functional characterisation of D470N mutant GLP2R 696 
 To investigate the functional differences between wild-type (WT) GLP2R and the D470N 697 
mutant GLP2R we generated D470N GLP2R mutant constructs using site-directed mutagenesis and 698 
characterised canonical GLP2R signalling pathways via cAMP as well as alternative signalling 699 
pathways via β-arrestin and P-ERK. 700 
Generation of D470N GLP2R mutant expressing constructs 701 
 Human GLP2R cDNA within the pcDNA3.1+ vector was purchased, and Gibson cloning was 702 
completed to insert an internal ribosome entry site (IRES) and venus gene downstream of the GLP2R 703 
sequence. Following this, QuikChange Lightning site directed mutagenesis was used to perform a 704 
single base change from GAC (encoding aspartic acid) to AAC (encoding asparagine) at amino acid 705 
position 470 (Supplemental Fig. 4A-B). Successful mutagenesis was confirmed by DNA Sanger 706 
sequencing (Supplemental Fig. 4C), and the successful products were scaled up for use in functional 707 
assays. The WT and mutant GLP2R constructs within the pcDNA3.1+ vector were used to assess 708 
signalling by cAMP and P-ERK. To determine β-arrestin recruitment using NanoBiT® technology, an 709 
alternative vector was required for lower expression of GLP2R, and fusion of GLP2R to the Large BiT 710 
subunit of NanoBiT®. For this, GLP2R was cloned into the pBiT1.1_C[TK/LgBiT] vector using 711 
restriction cloning and ligation. DNA Sanger sequencing was then used for confirmation of successful 712 
cloning.  713 
Comparison of WT and D470N GLP2R signalling via cAMP 714 
After generation of WT and D470N GLP2R containing constructs, these were used to assess 715 
differences in WT and mutant GLP2R signalling. The initial signalling pathway to be assessed was Gαs 716 
signalling via cAMP. CHO K1 cells were transiently transfected with WT or mutant GLP2R constructs, 717 
then after 16-24 hours were treated with a dose response of GLP-2. cAMP levels were measured 718 
following 30 minutes of GLP-2 treatment, in an end-point lysis HitHunter® cAMP assay. The presence 719 
of IRES-Venus within the GLP2R expressing vectors allowed transfection efficiency to be determined 720 
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for each construct. Transfection efficiency was approximately 60-70%, with no differences between 721 
the WT and mutant constructs. Comparison of the GLP-2 dose-response in WT and mutant GLP2R 722 
expressing cells revealed no significant differences in signalling, with an almost overlapping dose 723 
response curve (Fig. 5E).  724 
Comparison of β-arrestin recruitment to the WT and D470N GLP2R 725 
Both β-arrestin 1 and β-arrestin 2 recruitment were assessed using a Nano-Glo® live cell 726 
assay in transiently transfected HEK293 cells. Briefly, the recruitment of β-arrestin to GLP2R brings 727 
the large and small BiT subunit of NanoBiT® together, resulting in increased luciferase activity. The 728 
top concentrations from the GLP-2 dose response in the cAMP assay (1–100 nmol/l GLP-2) were 729 
chosen for stimulation of the GLP2R and observation of β-arrestin recruitment. Both β-arrestin 1 and 730 
β-arrestin 2 were recruited to the WT GLP2R upon GLP-2 stimulation, in a dose-dependent manner 731 
(Supplemental Fig. 5a, c). The maximal luciferase activity for both β-arrestin 1 and β-arrestin 2 732 
recruitment to the mutant GLP2R was significantly decreased when compared to the WT GLP2R, 733 
indicating the extent of β-arrestin recruitment was markedly decreased (Supplemental Fig. 5b, d). 734 
The example traces indicate that neither β-arrestin 1 or β-arrestin 2 were recruited to the mutant 735 
GLP2R upon stimulation with 1 nmol/l GLP-2, however the same concentration of GLP-2 induced β-736 
arrestin recruitment to the WT GLP2R. Overall there was a significant decrease in β-arrestin 1 and β-737 
arrestin 2 recruitment to the D470N GLP2R mutant (Figure 5F-G). 738 
Genetic score and Mendelian randomization analysis for macular telangiectasia type 2  739 
 For each metabolite a genetic score (GS) was calculated using all variants meeting genome-740 
wide significance and their beta-estimates as weights obtained from the meta-analysis of studies for 741 
which individual level data was available. We used fixed-effect meta-analysis to test for the effect of 742 
the GS on MacTel risk using the summary statistics from the most recent GWAS. A conservative 743 
Bonferroni-correction for the number of tested GS’s was used to declare significance (p<3.5x10-4). 744 
Sensitivity analyses were performed where the pleiotropic GCKR variant was removed.     745 
 To test for causality between circulating levels of glycine and serine for MacTel we 746 
performed two types of Mendelian randomization (MR) analysis. In a two-sample univariable MR56 747 
we tested for an individual effect of serine (n=4 SNPs) or glycine (n=15 SNPs) on the risk of MacTel 748 
using independent non-pleiotropic (i.e. the variant in GCKR) genome-wide SNPs as instruments. To 749 
this end, we used the inverse variance weighted method to pool SNP ratio estimates using random 750 
effects as implemented in the R package MendelianRandomization. SNP effects on the risk for 751 
MacTel were obtained from28. To disentangle the individual effect of those two highly correlated 752 
metabolites at the same time we used a multivariable MR model57 including all SNPs related to 753 
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serine or glycine (n=15 SNPs). Beta estimates and standard errors for both metabolites and all SNPs 754 
were obtained from the summary statistics and mutually used as exposure variables in multivariable 755 
MR. Effect estimates were again pooled using a random effect model as implemented in the R 756 
package MendelianRandomization. This procedure allowed us to obtain causal estimates for both 757 
metabolites while accounting for the effect on each other. Estimates can be interpreted as increase 758 
in risk for MacTel per 1 SD increase in metabolite levels while holding the other metabolite constant.   759 
 To estimate a potential clinical usefulness of the identified variants we constructed two 760 
GRS’s for MacTel using a) sex, the first genetic principal component, and the SNPs rs73171800 and 761 
rs9820286 which were identified by the MacTel GWAS study28 but not found to be related to either 762 
glycine or serine in our study and b) all the previous but additionally including genetically predicted 763 
serine and glycine at individual levels, via GS, to the model. An interaction between serine and sex at 764 
birth was included to reflect the interaction between SNP rs715 and sex as previously identified 28. 765 
To assess the predictive ability of both models, receiver operating characteristic curves were 766 
computed based on prediction values in 1,733 controls and 476 MacTel cases. 767 
Identification of genes related to inborn errors of metabolism 768 
 Biologically or genetically assigned candidate genes were annotated for IEM association 769 
using the Orphanet database32. Using a binomial two-tailed test, enrichment of metabolic loci was 770 
assessed by comparing the annotated list with the full list of 784 IEM genes in Orphanet against a 771 
backdrop of 19,817 protein-coding genes58. IEM-annotated loci for which the associated metabolite 772 
matched or was closely biochemically related to the IEM corresponding metabolite(s) based on 773 
IEMBase59 were considered further for analysis.  774 
 We hypothesised that IEM-annotated loci with metabolite-specific consequences could also 775 
have phenotypic consequences similar to the IEM. To test this, we first obtained terms describing 776 
each IEM and translated them into IEM-related ICD-10 codes using the Human Phenotype Ontology 777 
and previously-generated mappings60,61. We obtained association statistics from the 85 IEM SNPs for 778 
phenotypic associations with corresponding ICD-codes among UK Biobank restricting to diseases 779 
with at least 500 cases (N=93, Fig. 7B, http://www.nealelab.is/uk-biobank). We tested locus-disease 780 
pairs meeting statistical significance (controlling the false discovery rate at 5% to account for 781 
multiple testing) for a common genetic signal with the corresponding locus-metabolite association 782 
using statistical colocalisation. Because of the hypothesis-driven nature of the approach, i.e. prior 783 
knowledge of the causal gene and metabolite effect for a given IEM, we adopted an FDR-based 784 
strategy to account for multiple testing. We further highlight only those examples with strong 785 
evidence for a shared genetic signal (see below).  786 
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Colocalisation analyses 787 
 We used statistical colocalisation62 to test for a shared genetic signal between a metabolite and 788 
a disease of interest. We obtained posterior probabilities (PP) of: H0 – no signal; H1 – signal unique 789 
to the metabolite; H2 – signal unique to the trait; H3 – two distinct causal variants in the same locus 790 
and H4 – presence of a shared causal variant between a metabolite and a given trait. PPs above 80% 791 
were considered highly likely. We used p-values and MAFs obtained from the summary statistics 792 
with default priors to perform colocalisation. 793 
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FIGURE LEGENDS 998 
 999 
Figure 1A Sample size by contributing study and technique for each of the 174 metabolites included. 1000 
B A three-dimensional Manhattan plot displaying chromosomal position (x-axis) of significant 1001 
associations (p <4.9×10-10, z-axis) across all metabolites (y-axis). Colours indicate metabolite groups. 1002 
C A top view of the 3D-Manhattan plot. Dots indicate significantly associated loci. Colours indicate 1003 
novelty of metabolite – locus associations. Loci with indication for pleiotropy have been annotated.  1004 
 1005 
Figure 2A Distribution of pleiotropy, i.e. number of associated metabolites, among loci identified in 1006 
the present study. B Distribution of polygenicity of metabolites, i.e. number of identified loci for 1007 
each metabolite under investigation. C Scatterplot comparing the estimated heritability of each 1008 
metabolite against the number of associated loci. Size of the dots indicates samples sizes. D 1009 
Heritability estimates for single metabolites. Colours indicate the proportion of heritability 1010 
attributed to single nucleotide polymorphisms (SNPs) with large effect sizes (β>0.25 per allele). E – 1011 
M SNP – metabolite association with indication of non-additive effects. Beta is an estimate from the 1012 
departure of linearity. N Barplot showing the increase in heritability and explained variance for each 1013 
SNP – metabolite pair when including non-additive effects. 1014 
 1015 
Figure 3A Scatterplot comparing the minor allele frequencies (MAF) of associated variants with 1016 
effect estimates from linear regression models (N loci=499). Colours indicate possible functional 1017 
consequences of each variant: maroon – nonsynonymous variant; blue – in strong LD (r2>0.8) with a 1018 
nonsynonymous variant and grey otherwise. B-D Distribution of effect sizes (B), allele frequencies 1019 
(C), and width of credible sets (D) based on the type of single nucleotide polymorphism (SNP) (0 – 1020 
non-coding or synonymous, 1 – in strong LD with nonsynonymous, 2 - nonsynonymous). E 1021 
Distribution of functional annotations of metabolite associated variants (red), trait-associated 1022 
variants (blue – continuous, purple – diseases) obtained from the GWAS catalogue, and all SNPs 1023 
included in the present genome-wide association studies. The inlet for exonic variants distinguishes 1024 
between synonymous (syn) and nonsynonymous variants (nsyn). 1025 
 1026 
Figure 4A Comparison between the hypothesis-free genetically prioritized versus biologically 1027 
plausible approaches used in the present study to assign candidate genes to metabolite associated 1028 
single nucleotide polymorphisms. The Venn-diagram displays the overlap between both approaches. 1029 
B Enrichment of genetically prioritized genes among biologically plausible or genes linked to inborn 1030 
errors of metabolism (IEM). C Proportion of genetically prioritized genes encoding for either 1031 
enzymes or transporters. 1032 
 1033 
Figure 5A Enrichment of associations with type 2 diabetes (T2D: 80,983 cases, 842,909 controls) 1034 
among metabolite-associated SNPs.  Blue dots indicate metabolite-SNPs and grey dots indicate a 1035 
random selection of matched control SNPs.  B Regional association plots for plasma citrulline, type 2 1036 
diabetes, body mass index, and fasting levels of glucose-dependent insulinotropic peptide (GIP) 1037 
focussing on the GLPR2 gene. Variants are coloured based on linkage disequilibrium with the lead 1038 
variant (rs17681684) for plasma citrulline. *Summary statistics for GIP were obtained from the more 1039 
densely genotyped study included in Almgren et al.24 (to increase coverage of genetic variants for 1040 
multi-trait colocalisation). C Individual association summary statistics for all citrulline associated 1041 
SNPs (coded by the citrulline increasing allele) for T2D and an inverse-variance weighted (IVW) 1042 
estimate pooling all effects. D Schematic sketch for the location of the missense variant induces 1043 
amino acid substitution in the glucagon-like peptide-2 receptor (GLP2R). E GLP-2 dose response 1044 
curves in cAMP assay for GLP2R wild-type and mutant receptors. The dose response curves of cAMP 1045 
stimulation by GLP-2 in CHO K1 cells transiently transfected with either GLP2R wild-type or mutant 1046 
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constructs. Data were normalised to the wild-type maximal and minimal response, with 100% being 1047 
GLP-2 maximal stimulation of the wild-type GLP2R, and 0% being wild-type GLP2R cells with buffer 1048 
only. Mean ± standard errors are presented (n=4).F-G Summary of wild-type and mutant GLP2R 1049 
beta-arrestin 1 and beta-arrestin 2 responses. Area under the curve (AUC) summary data (n=3-4) 1050 
displayed for beta-arrestin 1 recruitment (E) and beta-arrestin 2 recruitment (F). AUCs were 1051 
calculated using the 5 minutes prior to ligand addition as the baseline value. Mean ± standard errors 1052 
are presented. Normal distribution of log10 transformed data was determined by the D'Agostino & 1053 
Pearson normality test. Following this statistical significance was assessed by one-way ANOVA with 1054 
post hoc Bonferroni test. ***p<0.001, *p<0.05. 1055 
 1056 
Figure 6A Results from genetic scores for each metabolite on risk for macular telangiectasia type 2 1057 
(MacTel). The dotted line indicates the level of significance after correction for multiple testing. The 1058 
inlet shows the same results but after dropping the pleiotropic variants in GCKR and FADS1-2. B 1059 
Effect estimates of serine-associated genetic variants on the risk for MacTel. C Comparison of effect 1060 
sizes for lead variants associated with plasma serine levels and the risk for MacTel. D Receiver 1061 
operating characteristic curves (ROC) comparing the discriminative performance for MacTel using a) 1062 
sex, the first genetic principal component, and two MacTel variants (rs73171800 and rs9820286) not 1063 
associated with metabolite levels, and b) additionally including genetically predicted serine and 1064 
glycine at individual levels as described in the methods. The area under the curve (AUC) is given in 1065 
the legend. 1066 
 1067 
Figure 7A Scheme of the workflow to link common variation in genes causing inborn errors of 1068 
metabolism (IEM) to complex diseases. 7B Flowchart for the systematic identification of metabolite-1069 
associated variants to genes and diseases related to inborn errors of metabolism (IEM). C P-values 1070 
from phenome-wide association studies among UK Biobank using variants mapping to genes 1071 
knowing to cause IEMs and binary outcomes classified with the ICD-10 code. Colours indicate 1072 
disease classes. The dotted line indicates the significance threshold controlling the false discovery 1073 
rate at 5%. D Posterior probabilities (PPs) from statistical colocalisation analysis for each significant 1074 
triplet consisting of a metabolite, a variant, and a ICD-10 code among UK Biobank. The dotted line 1075 
indicates high likelihood (>80%) for one of the four hypothesis tested: H0 – no signal; H1 – signal 1076 
unique to the metabolite; H2 – signal unique to the trait; H3 – two distinct causal variants in the 1077 
same locus and H4 – presence of a shared causal variant between a metabolite and a given trait. 1078 





Table 1 Genomic loci with effect sizes larger than 0.25 units in standard deviation of metabolite 1082 
levels per allele. 1083 
rsID Position* Metabolite EA/OA EAF N MA p-value Beta (se)** Candidate genes Expl. var. (%) 
rs13538 2:73868328 Acetylornithine A/G 0.78 30692 1.99E-1984 0.85 (0.01) NAT8, ACTG2 18.4
rs3916 12:121177272 Butyrylcarnitine C/G 0.26 30694 1.67E-2010 0.81 (0.01) ACADS,  16.9
rs12587599 14:104575130 Asparagine T/C 0.14 23606 8.98E-294 0.49 (0.013) ASPG, ADSSL1 8.2
rs3970551 22:18906839 Proline G/A 0.11 23618 1.10E-224 0.48 (0.015) PRODH 5.0 
rs174547 11:61570783 lysoPC a C20:4 T/C 0.67 16829 4.42E-398 0.47 (0.015) FADS1, DAGLA 9.9 
rs174545 11:61569306 PC aa C38:4 C/G 0.67 16828 1.37E-361 0.45 (0.015) FADS1,  9.2 
rs715 2:211543055 Glycine C/T 0.31 80000 3.00E-1632 0.44 (0.006) CPS1, IDH1 12.9 
rs174564 11:61588305 PC ae C42:3 A/G 0.66 9363 5.72E-183 0.44 (0.015) FADS1, DAGLA 8.9 
rs174547 11:61570783 PC aa C36:4 T/C 0.67 16830 3.25e-313 0.43 (0.015) FADS1, DAGLA 8.6 
rs1171617 10:61467182 Carnitine T/G 0.77 31001 2.06E-444 0.43 (0.011) SLC16A9,  7.0 
rs102275 11:61557803 PC ae C40:5 T/C 0.67 16839 8.23E-202 0.43 (0.015) C11orf10, DAGLA 8.7 
rs7157785 14:64235556 PC aa C28:1 T/G 0.16 16833 4.60E-136 0.35 (0.019) SGPP1,SYNE2 3.3 
rs174547 11:61570783 PC ae C36:5 T/C 0.67 16828 2.48E-185 0.33 (0.015) FADS1, DAGLA 5.1 
rs102275 11:61557803 PC aa C38:5 T/C 0.67 16836 8.31E-198 0.33 (0.015) C11orf10, DAGLA 5.0 
rs174564 11:61588305 PC ae C42:2 A/G 0.66 9363 7.04E-99 0.32 (0.015) FADS1, DAGLA 4.8 
rs174564 11:61588305 lysoPC a C26:1 A/G 0.66 9363 1.38E-91 0.32 (0.016) FADS1, DAGLA 4.6
rs7157785 14:64235556 SM (OH) C14:1 T/G 0.16 16833 1.65E-96 0.29 (0.019) SGPP1 2.2
rs174546 11:61569830 PC aa C24:0 C/T 0.67 13184 4.16E-89 0.29 (0.016) FADS1, DAGLA 3.6
rs174546 11:61569830 PC ae C38:5 C/T 0.67 16839 8.98E-146 0.29 (0.015) FADS1, DAGLA 3.9
rs7552404 1:76135946 Octanoylcarnitine A/G 0.69 31969 2.30E-260 0.28 (0.01) ACADM 2.8
rs1171615 10:61469090 Propionylcarnitine T/C 0.77 32590 7.09E-185 0.27 (0.011) SLC16A9 3.1
rs1171617 10:61467182 Acetylcarnitine T/G 0.77 31008 1.92E-156 0.27 (0.011) SLC16A9  3.3
rs2286963 2:211060050 Nonaylcarnitine G/T 0.36 13925 5.46E-159 0.26 (0.016) ACADL 3.2
rs12210538 6:110760008 Octadecandienylcarnitine A/G 0.77 30227 1.69E-144 0.26 (0.011) SLC22A16 1.0 
rs102275 11:61557803 PC aa C36:5 T/C 0.66 16835 2.09E-120 0.25 (0.015) C11orf10, DAGLA 3.0 
rs174550 11:61571478 PC ae C36:3 C/T 0.33 16830 2.05E-105 0.25 (0.015) FADS1, DAGLA 2.7 
EA = effect allele; OA = other allele; MA = meta-analysis; se = standard error; *Chromosome:Position based on Genome 1084 
Reference Consortium Human Build 37; **based on meta-analysis across cohorts for which individual-level data was 1085 
available (more information is provided in Supplementary Tab. S2). 1086 




Table 2 Results from Mendelian randomisation (MR) analysis between metabolite levels and risk of  1089 
macular telangiectasia type 2. 1090 
 1091 
Metabolite Univariable MR Multivariable MR 
Serine (4 SNPs)   
Odds ratio per SD increase 0.06 (0.03; 0.13) 0.10 (0.05; 0.21) 
p-value 9.45x10-12 2.95x10-9 
Glycine (15 SNPs)   
Odds ratio per SD increase 0.17 (0.08; 0.37) 0.50 (0.29; 0.87) 
p-value 9.99x10-6 1.35x10-2
MR estimates are based on the inverse variance-weighted method using random effects to pool estimates.  All single 1092 
nucleotide polymorphisms (SNPs) significantly associated with either serine or glycine have been included in multivariable 1093 
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